

Krzysztof Simon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6242899/publications.pdf>

Version: 2024-02-01

87
papers

3,040
citations

361413

20
h-index

168389

53
g-index

90
all docs

90
docs citations

90
times ranked

4157
citing authors

#	ARTICLE	IF	CITATIONS
1	HCV Genotype Has No Influence on the Incidence of Diabetes – EpiTer Multicentre Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 379.	2.4	2
2	Liver Injury in Patients with COVID-19 without Underlying Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 308.	2.4	13
3	Analysis of Deaths among HIV-Infected Patients Hospitalized in 2009–2018 in Main Centre of Infectious Disease in Region of Lower Silesia in Poland, Detailing Lesions in the Central Nervous System. <i>Medicina (Lithuania)</i> , 2022, 58, 270.	2.0	1
4	Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. <i>Vaccines</i> , 2022, 10, 557.	4.4	15
5	Application of a Web-based Self-assessment Triage Tool During the COVID-19 Pandemic: Descriptive Study. <i>JMIR Human Factors</i> , 2022, 9, e34134.	2.0	0
6	Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study. <i>Translational Oncology</i> , 2021, 14, 100943.	3.7	14
7	The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. <i>Vaccines</i> , 2021, 9, 109.	4.4	97
8	Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. <i>Viruses</i> , 2021, 13, 436.	3.3	24
9	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. <i>Journal of Clinical Medicine</i> , 2021, 10, 1583.	2.4	21
10	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 487-496.	0.4	48
11	Value of quantitative analysis in lung computed tomography in patients severely ill with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0251946.	2.5	11
12	Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study. <i>Cells</i> , 2021, 10, 1293.	4.1	20
13	Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. <i>World Journal of Gastroenterology</i> , 2021, 27, 2177-2192.	3.3	5
14	The chest radiographic scoring system in initial diagnosis of COVID-19: Is a radiologist needed?. <i>Advances in Clinical and Experimental Medicine</i> , 2021, 30, 797-803.	1.4	2
15	Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3280.	2.4	13
16	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 781.	4.4	28
17	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 649-658.	8.1	58
18	Endothelial Activation and Stress Index (EASIX) as an Early Predictor for Mortality and Overall Survival in Hematological and Non-Hematological Patients with COVID-19: Multicenter Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4373.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. <i>Annals of Gastroenterology</i> , 2021, 34, 438-446.	0.6	2
20	When Conventional Oxygen Therapy Fails—The Effectiveness of High-Flow Nasal Oxygen Therapy in Patients with Respiratory Failure in the Course of COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 4751.	2.4	8
21	Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. <i>Polish Archives of Internal Medicine</i> , 2021, 131, .	0.4	6
22	Real-world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1238-1246.	2.8	9
23	Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. <i>Advances in Medical Sciences</i> , 2020, 65, 12-17.	2.1	5
24	Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 163-169.	1.3	14
25	Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit “High mortality rate in infected patients with haematologic malignancies. <i>Journal of Clinical Virology</i> , 2020, 130, 104574.	3.1	35
26	Searching for the optimal population for hepatitis C virus screening in Poland. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 74-76.	1.3	3
27	Serum concentrations of selected adipokines in virus-related liver cirrhosis and hepatocellular carcinoma. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 235-242.	1.3	4
28	Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfecting patients treated with DAA. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1045-1054.	4.4	12
29	Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC). <i>PLoS ONE</i> , 2020, 15, e0227459.	2.5	16
30	Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 163-172.	0.4	14
31	Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 352-357.	0.4	51
32	Severe course of COVID-19 in a middle-aged man without risk factors. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 330-331.	0.4	1
33	Gastrointestinal symptoms as the first, atypical indication of SARS-CoV-2 infection. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 338-339.	0.4	11
34	Rapid progression of lung inflammatory infiltrates in SARS-CoV-2 infection in a young man. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 326-327.	0.4	1
35	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 915-918.	0.4	30
36	Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns. <i>Kardiologia Polska</i> , 2020, 78, 811-817.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Usefulness of portable chest radiography in initial diagnosis of COVID-19. Polish Archives of Internal Medicine, 2020, 130, 906-909.	0.4	6
38	Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. Journal of Viral Hepatitis, 2019, 26, 1156-1163.	2.0	17
39	Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-9.	1.9	12
40	Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (LAPLUS 2). Hepatology, 2019, 70, 1336-1348.	7.3	111
41	Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBsAg-positive chronic hepatitis B infection: ARES long-term follow-up. Journal of Viral Hepatitis, 2019, 26, 109-117.	2.0	20
42	Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?. Journal of Interferon and Cytokine Research, 2018, 38, 93-100.	1.2	9
43	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology, 2018, 67, 1754-1767.	7.3	528
44	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. BMC Infectious Diseases, 2018, 18, 580.	2.9	2
45	Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clinical and Experimental Hepatology, 2018, 4, 153-157.	1.3	15
46	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. Hepatitis Monthly, 2018, 18, .	0.2	2
47	Influence of Diabetes on Circulating Apoptotic Microparticles in Patients with Chronic Hepatitis C. In Vivo, 2018, 31, 1027-1034.	1.3	3
48	Effectiveness and safety of ledipasvir/sofosbuvir ± ribavirin in the treatment of HCV infection: The real-world HARVEST study. Advances in Medical Sciences, 2017, 62, 387-392.	2.1	23
49	Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. BMJ Case Reports, 2017, 2017, bcr-2017-220152.	0.5	1
50	The risk of complications of endoscopic procedures in patients with liver cirrhosis. Clinical and Experimental Hepatology, 2017, 3, 135-140.	1.3	14
51	Recommendations for the treatment of hepatitis C in 2017. Clinical and Experimental Hepatology, 2017, 2, 47-55.	1.3	34
52	Recommendations for the treatment of hepatitis B in 2017. Clinical and Experimental Hepatology, 2017, 2, 35-46.	1.3	15
53	Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts " 2016. Clinical and Experimental Hepatology, 2016, 2, 27-33.	1.3	16
54	Efficacy of HCV treatment in Poland at the turn of the interferon era " the EpiTer study. Clinical and Experimental Hepatology, 2016, 4, 138-143.	1.3	16

#	ARTICLE	IF	CITATIONS
55	Prevalence of HCV genotypes in Poland – the EpiTer study. <i>Clinical and Experimental Hepatology</i> , 2016, 4, 144-148.	1.3	18
56	Evaluation of hepatic fibrosis – access to non-invasive methods, national practice/guidelines in Central Europe. <i>Clinical and Experimental Hepatology</i> , 2016, 1, 12-15.	1.3	7
57	Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. <i>Hepatology International</i> , 2016, 10, 779-788.	4.2	17
58	Original article Distribution of HBV genotypes in Poland. <i>Clinical and Experimental Hepatology</i> , 2015, 1, 1-4.	1.3	9
59	Recommendations for treatment of hepatitis C. Polish Group of HCV Experts – 2015. <i>Clinical and Experimental Hepatology</i> , 2015, 3, 97-104.	1.3	4
60	Diagnostic Challenges in Primary Hepatocellular Carcinoma: Case Reports and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.3	8
61	Nutrition principles and recommendations in different types of hepatic encephalopathy. <i>Clinical and Experimental Hepatology</i> , 2015, 4, 121-126.	1.3	4
62	Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study). <i>Hepatology</i> , 2015, 61, 1512-1522.	7.3	145
63	Tissue laser biostimulation promotes post-extraction neoangiogenesis in HIV-infected patients. <i>Lasers in Medical Science</i> , 2015, 30, 701-706.	2.1	15
64	Manganese Encephalopathy among Ephedron Abusers – Case Reports. <i>Journal of Neuroimaging</i> , 2015, 25, 832-835.	2.0	12
65	Impact of vaccination against HBV on hepatitis B incidence in Opolskie province in 2007-2011. <i>Przegląd Epidemiologiczny</i> , 2015, 69, 27-31, 135-8.	0.2	1
66	Recommendations for elastography-based imaging of liver. <i>Przegląd Epidemiologiczny</i> , 2015, 69, 317-21, 429-33.	0.2	2
67	Chronic Hepatitis B Treatment Initiation and Modification Patterns in Five European Countries: A 2-Year Longitudinal, Non-Interventional Study. <i>Antiviral Therapy</i> , 2014, 19, 235-243.	1.0	8
68	Chronic Hepatitis B Monitoring and Treatment Patterns in Five European Countries with Different Access and Reimbursement Policies. <i>Antiviral Therapy</i> , 2014, 19, 245-257.	1.0	20
69	DRESS syndrome as a complication of treatment of hepatitis C virus-associated post-inflammatory liver cirrhosis with peginterferon α 2a and ribavirin. <i>Postepy Dermatologii I Alergologii</i> , 2014, 6, 401-404.	0.9	3
70	Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha–ribavirin treatment. <i>Journal of Medical Virology</i> , 2013, 85, 441-448.	5.0	14
71	Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , 2013, 97, 312-317.	4.1	16
72	of African tick-bite fever from Poland. <i>Postepy Dermatologii I Alergologii</i> , 2013, 6, 396-398.	0.9	5

#	ARTICLE	IF	CITATIONS
73	Distribution of HCV genotypes in Poland. <i>Przegląd Epidemiologiczny</i> , 2013, 67, 11-6, 99-103.	0.2	17
74	Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon- α 2B: Relation to Response and HBV Genotype. <i>Antiviral Therapy</i> , 2012, 17, 9-17.	1.0	63
75	Picolinic Acid in Patients with Chronic Hepatitis C Infection: A Preliminary Report. <i>Mediators of Inflammation</i> , 2012, 2012, 1-10.	3.0	9
76	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α 2a. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1012-1019.	1.6	11
77	Rapid Decline of Viral RNA in Chronic Hepatitis C Patients Treated Once Daily with IDX320: A Novel Macrocytic HCV Protease Inhibitor. <i>Antiviral Therapy</i> , 2012, 17, 633-642.	1.0	6
78	Surveillance programs for early detection of hepatocellular carcinoma. <i>Współczesna Onkologia</i> , 2012, 4, 295-305.	1.4	2
79	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 67-75.	7.3	75
80	Safety and Effectiveness of Blind Percutaneous Liver Biopsy: Analysis of 1412 Procedures. <i>Hepatitis Monthly</i> , 2012, 12, 32-37.	0.2	42
81	Prevalence and risk factors of HCV infection in Poland. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1213-1217.	1.6	49
82	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	3.9	333
83	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. <i>Hepatology</i> , 2010, 52, 454-461.	7.3	215
84	A Randomized Trial of Peginterferon α 2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2010, 105, 1762-1769.	0.4	83
85	Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α 2b. <i>Gastroenterology</i> , 2008, 135, 459-467.	1.3	373
86	Retinol- α vitamin A in HIV-infected patients who are former intravenous drug users. <i>Nutrition Research</i> , 2004, 24, 427-434.	2.9	1
87	Clinical and epidemiological assessment of hepatitis C virus infection among voluntary blood donors. <i>Medical Science Monitor</i> , 2002, 8, CR591-6.	1.1	2